Porton Advanced’s Innovative Solutions Propel Salvectors' Therapy Approval in China and the US#China#Suzhou#Porton_Advanced#Oncolytic_Therapy#Salvectors
Porton Advanced’s Innovative Solutions Propel Salvectors' Therapy Approval in China and the US
Porton Advanced's comprehensive CDMO services have successfully accelerated Salvectors' innovative oncolytic bacteria therapy approval in the US and China.
third-news.com
May 28, 2026 at 11:10 AM
Porton Advanced’s Innovative Solutions Propel Salvectors' Therapy Approval in China and the US#China#Suzhou#Porton_Advanced#Oncolytic_Therapy#Salvectors
Porton Advanced Achieves Class C Drug Manufacturing License to Boost CDMO Capabilities#China#Suzhou#Porton_Advanced#Drug_Manufacturing#CGT_Solutions
Porton Advanced Achieves Class C Drug Manufacturing License to Boost CDMO Capabilities
Porton Advanced Solutions recently obtained a Class C Drug Manufacturing License, enhancing its capacity for commercial contract manufacturing in the CGT sector.
third-news.com
August 5, 2026 at 12:15 PM
Porton Advanced Achieves Class C Drug Manufacturing License to Boost CDMO Capabilities#China#Suzhou#Porton_Advanced#Drug_Manufacturing#CGT_Solutions
Porton Advanced Solutions Receives Key Drug Manufacturing License to Enhance CDMO Services#China#Suzhou#CDMO_Services#Porton_Advanced#Drug_Manufacturing
Porton Advanced Solutions Receives Key Drug Manufacturing License to Enhance CDMO Services
Porton Advanced Solutions Ltd. has secured a Class C Drug Manufacturing License in China, enabling enhanced services in cell and gene therapy manufacturing.
third-news.com
August 5, 2026 at 11:45 AM
Porton Advanced Solutions Receives Key Drug Manufacturing License to Enhance CDMO Services#China#Suzhou#CDMO_Services#Porton_Advanced#Drug_Manufacturing
Porton Advanced Marks a Major Milestone with FDA Acceptance of UC-MSCs Cell Bank for Exosome Production#United_States#exosome_therapy#Porton_Advanced#Cranbury,_NJ#UC-MSCs
Porton Advanced Marks a Major Milestone with FDA Acceptance of UC-MSCs Cell Bank for Exosome Production
Porton Advanced's new UC-MSCs Cell Bank for exosome production has received FDA acceptance, enhancing their position in the exosome therapy market.
third-news.com
July 8, 2026 at 2:10 PM
Porton Advanced Marks a Major Milestone with FDA Acceptance of UC-MSCs Cell Bank for Exosome Production#United_States#exosome_therapy#Porton_Advanced#Cranbury,_NJ#UC-MSCs
Porton Advanced Achieves FDA Drug Master File Acceptance for UC-MSCs Cell Bank in Exosome Production#USA#Cranbury#Porton_Advanced#UC-MSCs#Exosome_Manufacturing
Porton Advanced Achieves FDA Drug Master File Acceptance for UC-MSCs Cell Bank in Exosome Production
Porton Advanced's UC-MSCs Cell Bank has received FDA Drug Master File acceptance, crucial for accelerating exosome manufacturing regulatory processes.
third-news.com
July 8, 2026 at 1:10 PM
Porton Advanced Achieves FDA Drug Master File Acceptance for UC-MSCs Cell Bank in Exosome Production#USA#Cranbury#Porton_Advanced#UC-MSCs#Exosome_Manufacturing
Porton Advanced Partners with Dark Horse Consulting for Clinical Trials in China#None#Porton_Advanced#Dark_Horse_Consulting#Investigator-Initiated_Trials#Cranbury,_New_Jersey,_and_Suzhou,_China
Porton Advanced Partners with Dark Horse Consulting for Clinical Trials in China
Porton Advanced and Dark Horse Consulting Group have signed an MOU to streamline the process of conducting Investigator-Initiated Trials in China, enhancing advanced therapy development.
third-news.com
May 13, 2026 at 12:51 PM
Porton Advanced Partners with Dark Horse Consulting for Clinical Trials in China#None#Porton_Advanced#Dark_Horse_Consulting#Investigator-Initiated_Trials#Cranbury,_New_Jersey,_and_Suzhou,_China
Porton Advanced's Stem Cell Exosomes Achieve INCI Status, Enhancing Their Global Market Reach#United_States#Cranbury#Porton_Advanced#Stem_Cell_Exosomes#INCI_Status
Porton Advanced's Stem Cell Exosomes Achieve INCI Status, Enhancing Their Global Market Reach
Porton Advanced has received INCI status for its stem cell-derived exosomes, marking a significant milestone in its expansion into global cosmetic markets.
third-news.com
May 13, 2026 at 10:50 AM
Porton Advanced's Stem Cell Exosomes Achieve INCI Status, Enhancing Their Global Market Reach#United_States#Cranbury#Porton_Advanced#Stem_Cell_Exosomes#INCI_Status
Porton Advanced Achieves INCI Status for Innovative Stem Cell Exosomes, Expanding into Global Cosmetic Market#United_States#Cranbury#Exosomes#Porton_Advanced#Cosmetic_Ingredients
Porton Advanced Achieves INCI Status for Innovative Stem Cell Exosomes, Expanding into Global Cosmetic Market
Porton Advanced's stem cell-derived exosomes have received INCI status, allowing entry into global cosmetics. The certification enhances their market reach and compliance.
third-news.com
May 13, 2026 at 7:25 AM
Porton Advanced Achieves INCI Status for Innovative Stem Cell Exosomes, Expanding into Global Cosmetic Market#United_States#Cranbury#Exosomes#Porton_Advanced#Cosmetic_Ingredients
Porton Advanced and EVA Pharma Collaborate to Enhance CAR T-Cell Therapy Access in MEA Region#CAR_T-cell_Therapy#Egypt#Cairo#Porton_Advanced#EVA_Pharma
Porton Advanced and EVA Pharma Collaborate to Enhance CAR T-Cell Therapy Access in MEA Region
Porton Advanced Solutions and EVA Pharma have signed an MOU to enhance access to CAR T-cell therapies in the Middle East and Africa, boosting local manufacturing and technology transfer.
third-news.com
June 26, 2025 at 1:55 PM
Porton Advanced and EVA Pharma Collaborate to Enhance CAR T-Cell Therapy Access in MEA Region#CAR_T-cell_Therapy#Egypt#Cairo#Porton_Advanced#EVA_Pharma
Porton Advanced Partners with TongEYE to Enhance Cell Therapy for Eye Diseases#China#Suzhou#Porton_Advanced#TongEYE#iPSC-RPEC
Porton Advanced Partners with TongEYE to Enhance Cell Therapy for Eye Diseases
Discover how Porton Advanced collaborates with TongEYE to expedite advancements in iPSC-RPEC transplantation therapy designed for blinding eye diseases.
third-news.com
May 22, 2025 at 1:13 PM
Porton Advanced Partners with TongEYE to Enhance Cell Therapy for Eye Diseases#China#Suzhou#Porton_Advanced#TongEYE#iPSC-RPEC
Porton Advanced and Hualong Biological Join Forces to Propel MATC Cell Therapy for Solid Tumors#China#Suzhou#Porton_Advanced#Hualong_Biological#MATC_Therapy
Porton Advanced and Hualong Biological Join Forces to Propel MATC Cell Therapy for Solid Tumors
Porton Advanced collaborates with Hualong Biological to enhance MATC cell therapy development aimed at solid tumors, streamlining the process and ensuring regulatory compliance.
third-news.com
May 19, 2025 at 1:46 PM
Porton Advanced and Hualong Biological Join Forces to Propel MATC Cell Therapy for Solid Tumors#China#Suzhou#Porton_Advanced#Hualong_Biological#MATC_Therapy
Porton Advanced Streamlines CDMO Support for Tasly's CAR-T Therapy Success#China#Suzhou#CAR-T_therapy#Porton_Advanced#Tasly_Pharma
Porton Advanced Streamlines CDMO Support for Tasly's CAR-T Therapy Success
Porton Advanced's comprehensive services expedite Tasly's CAR-T therapy's IND approval, paving the way for innovative cancer treatment in patients.
third-news.com
April 16, 2025 at 1:28 PM
Porton Advanced Streamlines CDMO Support for Tasly's CAR-T Therapy Success#China#Suzhou#CAR-T_therapy#Porton_Advanced#Tasly_Pharma
Porton Advanced Partners with Eureka Therapeutics to Enhance T-Cell Therapy Progression#United_States#Cranbury#T-Cell_Therapy#Porton_Advanced#Eureka_Therapeutics
Porton Advanced Partners with Eureka Therapeutics to Enhance T-Cell Therapy Progression
Porton Advanced collaborates with Eureka Therapeutics to expedite T-cell therapy development, leveraging advanced manufacturing capabilities.
third-news.com
March 19, 2025 at 2:28 PM
Porton Advanced Partners with Eureka Therapeutics to Enhance T-Cell Therapy Progression#United_States#Cranbury#T-Cell_Therapy#Porton_Advanced#Eureka_Therapeutics